https://doi.org/10.55788/945c4d18
Dr Chiara Ciccarese (Agostino Gemelli University Policlinic, Italy) presented the preliminary findings of the phase 2 TACITO trial (NCT04758507), which explored the use of FMT versus placebo in patients receiving pembrolizumab and axitinib for metastatic RCC [1]. The study focused on the role of gut microbiota in influencing the efficacy of ICIs, particularly in RCC, where it has been shown that the composition of the intestinal microbiota may affect response to ICIs [2].
The TACITO trial aimed to determine whether FMT from a patient who had responded to treatment could enhance the anti-tumour activity of pembrolizumab and axitinib in treatment-naïve metastatic RCC patients. The participants (n=50) were randomised 1:1 to receive either FMT or placebo at 3 intervals alongside standard treatment with pembrolizumab and axitinib. The primary endpoint of the study was the proportion of participants free from progression after 1 year.
The 1-year progression-free survival (PFS) rate was significantly higher in the FMT group compared with the placebo group (66.7% vs 35.0%; P=0.036). The median PFS was also extended, with participants who received FMT achieving a median of 14.2 months, compared with 9.2 months in the placebo group. The overall response rate (ORR) was 52% in the FMT group, compared with 28% in the placebo group, although no complete responders were identified in either cohort. The overall survival (OS) was not reached in the intervention arm, whereas it was 25.3 months in the placebo group.
Despite some challenges with administering FMT, Dr Ciccarese highlighted that the procedure was well tolerated, with no severe adverse events reported. “The preliminary results suggest that FMT could play a significant role in enhancing the efficacy of ICI and VEGFR TKI therapies in metastatic RCC,” she explained. However, she stressed that longer follow-up is necessary to fully assess the impact of FMT on OS and median PFS.
Further microbiome analysis is ongoing to better understand the changes in gut microbiota before and after FMT. Dr Ciccarese concluded that while these early findings are encouraging, they warrant further investigation in larger, randomised trials to explore the potential of FMT as a complementary treatment in metastatic RCC.
- Ciccarese C, et al. Fecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma: Preliminary results of the randomized phase II TACITO trial. Abstract LBA77, ESMO Congress 2024, 13–17 September, Barcelona, Spain.
- Zugman M, et al. Urol Oncol. 2024 Aug 1:S1078-1439(24)00540-4.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« More highlights in Renal Cell Carcinoma Next Article
Watchful waiting is non-inferior to BCG in patients with T0 after second transurethral resection »
« More highlights in Renal Cell Carcinoma Next Article
Watchful waiting is non-inferior to BCG in patients with T0 after second transurethral resection »
Table of Contents: ESMO 2024
Featured articles
Meet the Trialist: Prof. Fred Saad shares insights from the ARANOTE trial
Gastrointestinal Cancer
Neoadjuvant chemoradiation does not improve surgical outcomes or survival in pancreatic cancer
Adding lenvatinib plus pembrolizumab to TACE improves PFS in intermediate-stage HCC
Benefit of adjuvant atezolizumab/bevacizumab in HCC not maintained over time
Pre-operative chemoradiation does not improve survival in resectable gastric cancer
Final results of the IKF-AIO-Moonlight trial
Gastrointestinal: Colorectal Cancer
Retifanlimab boosts survival in patients with anal cancer
NICHE-2 and NICHE-3 show high efficacy of short neoadjuvant immunotherapy in dMMR colon cancer
Organ-preserving regimens in rectal cancer
No benefit of high-dose vitamin D3 supplementation in mCRC
Breast Cancer
Trastuzumab deruxtecan also effective in patients with brain metastases
High pCR rates with dual neoadjuvant immunotherapy in TIL-high TNBC
Local HER2 IHC0 is often HER2-low or -ultralow
First-line capivasertib improves PFS but not OS in metastatic TNBC
Breastfeeding does not increase the risk of breast cancer recurrence
Lung Cancer
Adjuvant durvalumab does not improve survival in completely resected NSCLC
NVL-655: a promising new option in pre-treated, drug-resistant ALK-mutated NSCLC
Relatlimab addition benefits only a subgroup of metastatic NSCLC
Melanoma
Neoadjuvant nivolumab/ipilimumab improves DMFS in stage III resectable melanoma
New neoadjuvant combinations in stage III melanoma
Genitourinary Cancer
Rethinking immune rechallenge: Tivozanib monotherapy emerges as a promising post-ICI option in metastatic RCC
Perioperative durvalumab combined with neoadjuvant chemotherapy improves survival in bladder cancer
Watchful waiting is non-inferior to BCG in patients with T0 after second transurethral resection
Faecal transplants show promise in enhancing metastatic RCC treatment
Genitourinary: Prostate Cancer
Combination of radium-223 and enzalutamide benefits patients with mCRPC with bone metastases
177Lu-PSMA effective both in mCRPC and mHSPC
Decipher score is predictive for docetaxel-benefit in mestastatic prostate cancer
Final OS for CONTACT-02 trial in mCRPC
Gynaecological Cancer
Increased OS with pembrolizumab in newly diagnosed, high-risk, locally advanced cervical cancer
Doublet maintenance therapy does not outperform monotherapy in ovarian cancer
Benefit of pembrolizumab in dMMR, newly diagnosed, high-risk endometrial cancer
No OS benefit of niraparib maintenance in high-risk ovarian cancer
Related Articles

August 5, 2022
Encouraging results of relacorilant in ovarian cancer
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com